Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Pharmacological Treatment in Women With Female Sexual Interest/Arousal Disorder (FSIAD). (FSIAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04433559
Recruitment Status : Not yet recruiting
First Posted : June 16, 2020
Last Update Posted : June 16, 2020
Sponsor:
Information provided by (Responsible Party):
Lidia Larrañaga, Laboratorios LITAPHAR, S.L.

Brief Summary:

This clinical trial is a prospective, randomized, double-blind Phase III study with two arms to determine the efficacy and safety of the use of an IPDE in women with FSIAD.

Patients who meet all inclusion criteria and do not meet any of the exclusion criteria will enter the study and receive active product or placebo for 14 weeks.

Patients will be assigned to each treatment group in a randomized and parallel manner. In addition, all volunteers participating in the study will receive medical advice during the study.

The study will have a duration of minimum of 18 weeks and will consist of 3 periods.


Condition or disease Intervention/treatment Phase
Sexual Dysfunctions, Psychological Drug: Tadalafil 1,5 mg oral tablets Drug: Placebo oral tablets Phase 3

Detailed Description:

This clinical trial is a prospective, randomized, double-blind Phase III study with two arms to determine the efficacy and safety of the use of an IPDE in women with FSIAD.

Patients who meet all inclusion criteria and do not meet any of the exclusion criteria will enter the study and receive active product or placebo for 14 weeks.

Patients will be assigned to each treatment group in a randomized and parallel manner. In addition, all volunteers participating in the study will receive medical advice during the study.

The study will have a duration of minimum of 18 weeks and will consist of 3 periods

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-blind, Two-arms Study With Parallel Groups to Determine the Effect of a Phosphodiesterase Inhibitor for 14 Weeks of Treatment Versus Placebo in Women With FSIAD.
Estimated Study Start Date : August 2020
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : August 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Tadalafil

Arm Intervention/treatment
Active Comparator: Group Active Tadalafile
One oral tablet of 1.5 mg IPDE daily for 14 weeks of treatment.
Drug: Tadalafil 1,5 mg oral tablets
Use of tadalafil in the treatment of FSIAD
Other Name: Tadalafil

Placebo Comparator: Group Placebo
One oral tablet of placebo daily for 14 weeks of treatment.
Drug: Placebo oral tablets
Use of placebo in control group
Other Name: Placebo




Primary Outcome Measures :
  1. Effect of IPDE (Tadalafile) according to FSFI (Female Sexual Function Index) [ Time Frame: 14 weeks ]

    To determine the effect of IPDE at a dose of 1.5 mg versus placebo in women with disorders of interest and sexual arousal using the FSFI (Female Sexual Function Index).

    FSFI contains 19 questions, with each questions with a value minimum of 0 and maximum of 6 points, beeing 0 the worst scenario y 6 the best scenario.



Secondary Outcome Measures :
  1. Comparative IPDE Vs placebo according to FSFI [ Time Frame: 14 weeks ]

    To compare the effect of IPDE with respect to placebo in women with disorders of interest and sexual arousal using the FSFI (Female Sexual Function Index).

    FSFI contains 19 questions, with each questions with a value minimum of 0 and maximum of 6 points, beeing 0 the worst scenario y 6 the best scenario.


  2. Comparaive of IPDE Vs placebo according NSSS-Short (New Sexual Satisfaction Scale) [ Time Frame: 14 weeks ]

    To compare the effect of IPDE with respect to placebo in women with disorders of interest and sexual arousal using the questionnaire "The New Sexual Satisfaction Scale" (NSSS-Short).

    NSSS-Short (New Sexual Satisfaction Scale) contains 7 questions, with each questions with a value minimum of 0 and maximum of 100 points, beeing 0 the worst scenario y 100 the best scenario.


  3. Comparative IPDE Vs placebo according to the TSQM (Treatment Satisfaction questionnaire for Medication) [ Time Frame: 14 weeks ]

    To compare the effect of IPDE with respect to placebo in women with disorders of interest and sexual arousal using the "Treatment Satisfaction questionnaire for Medication" (TSQM) version 1.4.

    TSQM (Treatment Satisfaction questionnaire for Medication) contains 14 questions with each questions with a value minimum of 0 and maximum of 80 points, beeing 0 the worst scenario y 80 the best scenario.


  4. Comparative of IPDE Vs placebo according to number of sexual events [ Time Frame: 14 weeks ]

    To compare the effect of IPDE with respect to placebo in women with sexual interest and arousal disorder by measuring the number of sexual events recorded in the weekly diary.

    The diary will be fullfilled by the women according to the number of sexual events.


  5. Comparative of IPDE Vs placebo according to the sexual satisfaction [ Time Frame: 14 weeks ]

    To compare the effect of IPDE with respect to placebo in women with sexual interest and arousal disorder by measuring the sexual satisfaction of sexual intercourse.

    The scale will contain 3 questions, with a visual analog scale. This visual analog scale will contain a scale with different visual easy identificable progesion faces, from very sad face to very happy face, beeging the first sad face, the no satisfaction point, and the last very happy face the very satisfactory sexual event point.


  6. Comparative of IPDE Vs placebo according to ease of arousal [ Time Frame: 14 weeks ]

    To compare the effect of IPDE with respect to placebo in women with disorder of interest and sexual arousal by measuring the ease of arousal during sexual intercourse determined using an analog visual scale.

    The scale will contain 3 questions, with a visual analog scale. This visual analog scale will contain a scale with different visual easy identificable progesion faces, from very sad face to very happy face, beeging the first sad face, the no satisfaction point, and the last very happy face the very satisfactory sexual event point.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Women between 18 and 65 years old. Women of childbearing age (premenopausal, not surgically sterilized at least 3 months before the Selection Visit) must be used during the study a highly effective contraceptive method such as:

    • contraceptive methods or partner vasectomy, and confirm who are not pregnant by pregnancy test negative in the Selection Consultation.

      2. Signature of the informed consent obtained in writing,including a data protection declaration before the participation in the study.

      3. Women with disorders of interest and sexual arousal diagnosed using a semi-structured questionnaire of 5 questions based on DSM-V criteria.

Exclusion Criteria :

  1. The following groups of patients with cardiovascular risk:

    • Patients who had suffered myocardial infarction in the 90s previous days,
    • Patients with unstable angina or angina produced during sexual activity,
    • Patients with heart failure corresponding to class II or higher than the New York Heart Association classification (NYHA) in the previous 6 months,
    • Patients with uncontrolled arrhythmias,
    • Patients who had suffered a stroke in the previous 6 months.
  2. Patients with disorders of female sexual arousal of origin neurogenic.
  3. Patients with female sexual dysfunction associated with disorders psychiatric.
  4. Patients with a partner who suffers from sexual dysfunction.
  5. Patients with dysphoric excitation disorder and / or with sensation unpleasant genital thickening.
  6. Patients with a history of severe thromboembolic disease, hepatic, renal, or neoplastic.
  7. Uncontrolled diabetic patients (HbA1c> 8% in the last control).
  8. Patients with depression and / or taking antidepressants.
  9. Lactation
  10. Hypersensitivity to tadalafil and / or drugs and products related (including excipients of the formulation).
  11. Patients undergoing treatment with any form of organic nitrate.
  12. Patients on treatment with potent CYP3A4 inhibitors (ritonavir, ketoconazole, itraconazole, clarithromycin, erythromycin, and saquinavir) and strong CYP3A4 inducers (carbamazepine, phenytoin, phenobarbital, St. John's wort, rifampin).
  13. Patients who have loss of vision in one eye a consequence of anterior ischemic optic neuropathy not arteritic.
  14. Patients with any pelvic surgery in the previous 6 months.
  15. Known history of drug and / or alcohol abuse in the 6 months prior to the selection consultation.
  16. Participation in another study in the 3 months prior to the consultation of selection.
  17. Any illness that, in the investigator's judgment, can interfere with compliance with study procedures or study evaluations.
  18. Patient with any medical or surgical condition that may interfere with absorption, distribution, metabolism or excretion of the study drug according to the criteria of the researcher.
  19. Patients in judicial or police custody.
  20. Patients with difficulties in understanding the language in which they gives the information to the subject.
  21. Patients who do not agree to the transmission of their anonymous data regarding the documentation and notification functions.
  22. Study center, sponsor or CRO staff, their own researcher or relatives of the same.
Layout table for additonal information
Responsible Party: Lidia Larrañaga, Clinical Trial Coordinator, Laboratorios LITAPHAR, S.L.
ClinicalTrials.gov Identifier: NCT04433559    
Other Study ID Numbers: LITA-004
First Posted: June 16, 2020    Key Record Dates
Last Update Posted: June 16, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sexual Dysfunctions, Psychological
Mental Disorders
Tadalafil
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents